Uridine triacetate

Overview

Uridine triacetate (INN), formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:[1][2] WP

in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/);[3] WP⚠ The source gives a pronunciation guide here that is not shown.

to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).[4–8] WP

Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.[9][10][11] WP

Chemistry

Formula

C15H18N2O9 PC

CAS number

4105-38-8 PC

Molar mass (g/mol)

370.31 PC

IUPAC name (computed by PubChem)

[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate PC

SMILES

CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C PC

InChIKey

AUFUWRKPQLGTGF-FMKGYKFTSA-N PC

PubChem CID

20058

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65
2. Harm reduction site Uridine triacetate — DrugBank Page. 12 March 2017
3. Journal / agency Xuriden- uridine triacetate granule. 16 December 2019
4. Journal / agency Vistogard- uridine triacetate granule. 15 November 2018
5. Other BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine. 11 December 2015
6. Journal / agency Approved Drugs — Uridine Triacetate
7. Journal / agency Cada DJ, Mbogu U, Bindler RJ, Baker DE. Uridine Triacetate. Hospital Pharmacy. June 2016. doi:10.1310/hpj5106-484 · PMID 27354750 · PMC4911989
8. Journal / agency Ison G, Beaver JA, McGuinn WD, Palmby TR, Dinin J, Charlab R, Marathe A, Jin R, Liu Q, Chen XH, Ysern X, Stephens O, Bai G, Wang Y, Dorff SE, Cheng J, Tang S, Sridhara R, Pierce W, McKee AE, Ibrahim A, Kim G, Pazdur R. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Clinical Cancer Research. September 2016. doi:10.1158/1078-0432.CCR-16-0638 · PMID 27401247
9. Journal / agency Xuriden (uridine triacetate) oral granules. 8 October 2015
10. Journal / agency Drug Trials Snapshots: Xuriden. 4 September 2015
11. Journal / agency Previous Cumulative CY CDER BT Approvals

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.